Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

$24.99

Price to Sales (P/S)
since 2005

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Pfizer Inc., P/S, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$

2 Data adjusted for splits and stock dividends.

3 Closing price as at the filing date of Pfizer Inc. Annual Report.


Share Price Trend
The share price exhibited notable fluctuations over the analyzed period. Beginning at $26.26, it declined gradually to a low of $12.31 by early 2009. After this trough, the price generally trended upwards, reaching a peak of $45.96 in 2022. Subsequently, the share price experienced a decline, decreasing to $26.10 by 2025. This pattern indicates periods of volatility with phases of recovery and correction.
Sales per Share Dynamics
Sales per share remained relatively stable in the initial years, fluctuating around the $6 to $8 range through 2011. From 2012 onwards, there was a general upward trend, peaking at $18.01 in 2023, which represents significant growth in per-share sales. However, a reduction followed, decreasing to $11.23 by 2025. This suggests periods of strong sales growth interspersed with a recent contraction.
Price-to-Sales (P/S) Ratio Analysis
The P/S ratio demonstrated variance throughout the period. It started moderately high at 3.77 in 2006, decreasing sharply to 1.72 by 2009, coinciding with the low share price and steady sales per share. Subsequently, the ratio increased again to a peak of 4.49 in 2019, indicating that share prices were rising faster than sales per share during this time. In the last years, the ratio declined to approximately 2.32 by 2025, reflecting either a relative decrease in share prices, an increase in sales per share, or both.
Overall Insights
The data indicates that while sales per share experienced overall growth with some volatility, the share price was more susceptible to market fluctuations, illustrating periods of investor optimism and concern. The P/S ratio movements suggest shifts in market valuation relative to sales, with especially high valuation multiples observed around 2019 before moderating in the subsequent years. This combination of trends suggests that market sentiment and sales performance have not always moved in tandem, reflecting external factors influencing investor perception and company valuation.

Comparison to Competitors

Pfizer Inc., P/S, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Pfizer Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)